Wisdom Pharmaceutical: Net profit is expected to be 12.3 million to 18.45 million in 2025, compared to -226 million in the same period last year.

Wisdom Pharmaceutical announced that it is expected to achieve a net profit of 12.3 million to 18.45 million yuan in 2025, compared to a loss of 226 million yuan in the same period last year. In 2025, the company's net profit attributable to shareholders of the listed company turned from a loss to a profit for the following reasons: With the recovery of global demand for innovative drugs, the company relies on its core competitiveness of the full-process R&D platform to continuously increase market development efforts, improve its ability to obtain orders, and drive growth in its main business income; The company is further advancing cost reduction and efficiency improvement measures, continuously optimizing cost control and resource allocation structure, and expects period expenses to decrease year-on-year, effectively improving profitability; The company recognized a goodwill impairment loss of 139 million yuan in 2024, and the related goodwill book value has been reduced to zero. Therefore, no additional goodwill impairment loss occurred in 2025.